06 JC02 Rec'd PCT/PTO 10 JUN 20

EXPRESS MAIL LAB NO.: EV517776154US

PATENT

Attorney Docket No. 27763-705.831

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

Inventor(s): Richard O. Chen et al.

Application No.: 10/502,420

Filed: July 23, 2004

Title Drug Discovery Method

PATENT APPLICATION

Art Unit: Not yet assigned

Examiner: Not yet assigned

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

⊠ apply)		tatemen	fies under 37 C.F.R. §1.97, subsection ecause (check all that		
•		(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR		
		(2)	It is being filed within 3 months of entry of a national stage OR		
	\boxtimes	(3)	It is being filed before the mail date of the first Office Action on the merits OR		
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.		
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three beyond the filing date of a national application; (2) three months beyond the date of the national stage as set forth in §1.491 in an international application; or mailing date of a first Office action on the merits, but before the mailing date earlier of a final office action under §1.113 or a notice of allowance under §1.311.				
		a certi	fication as specified in §1.97(e) is provided below; or		
			of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included the payment of other papers filed together with this statement.		
	37 C.F.R. $\S1.97(d)$. If this statement is being filed after the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$, but before payment of the issue fee, then:				
	A.	a certi	fication as specified in §1.97(e) is completed below; and		
	B.		ion under 37 C.F.R. §1.97(d) requesting consideration of this statement is tted herewith; and		
	C.		of \$130.00 as set forth in \$1.17(i)(1) is authorized below, enclosed, or ed with the payment of other papers filed together with this statement.		
\boxtimes	Copies herewi		ch of the references listed on the attached Form PTO-1449 are enclosed		
\boxtimes	_	s of ref PT THA	ferences listed on the attached Form PTO-1449 are enclosed herewith AT:		
		referer	w of the voluminous nature of references, and the likelihood that these nces are available to the Examiner in the file history of the parent ation (Serial No.), copies are not enclosed herewith.		
		•	of the foregoing publications are not available to the Examiner, Applicant ideavor to supply copies at the Examiner's request.		
	\boxtimes	accord	s of only foreign patent documents and non-patent literature are enclosed in ance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent ation publication listed on the attached Form PTO-1449 are not enclosed		

•		internation application has entered	on was filed aft rune 30, 2003 or this the national stage under 35 USC §371 after frequirement under 37 CFR 1.98 (a)(2)(i).			
		are not in the English language.				
		The relevance of those listed reference as follows:	hose listed references which are not in the English language is			
		Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.				
	Attached are the following non-published pending patent applications w be deemed relevant, which are listed on the attached Submission Und 609 D.					
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No.27763-705.831).					
			Respectfully submitted,			
			WILSON SONSINI GOODRICH & ROSATI			
Dated:		6 10 05	By: A si Par			
TRIPIC ROOM						
	ge Mill	94304-1050				
	110, CA 193 - 930					
` '	stomer No. 021971					

PTO/SB/08A (08-03)

Approve through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Onne; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/I/TO Complete if Known Application Number 10/502,420	Under the paperwork Reduction According to persons required to respond to a collection of information unless it contains a valid OMB control number							
Substitute for form 1449/I/TO Supplication Number 10/502,420								
INFORMATION DISCUBSURE Filing Date July 23, 2004								
STATEMENT BY EPPLICANT Series First Named Inventor Richard O. Chen et al.								
(Use as many sheets as Cessary) Art Unit Not yet assigned Examiner Name Not yet assigned								
Examiner Name Not yet assigned								
Sheet 1 of 2 Attorney Docket Number 27763-705.831								

U.S. PATENT DOCUMENTS							
Examiner	Cite	Name of Patentee or	Pages, Columns, Lines, Where				
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ³ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te	
	_	EP1158447 A1	11-28-2001	Ralf Zimmer et al.			
		WO 01/55911 A1	8-2-2001	Vadim Babenko			
,							

	1	 	
			-
Examiner		Date	
Signature		Considered	

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

2587611_1.DOC.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant¹s unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) se through 07/31/2006. OMB 0651-0031 Approv U.S. Patent and Trademark Ornce; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction s required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449 PTO JUN 1 0 2005 Application Number 10/502,420 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Filing Date July 23, 2004 First Named Inventor Richard O. Chen et al. Art Unit Not yet assigned **Examiner Name** Not yet assigned ... 27763-705.831 Attorney Docket Number 2 of 2 Sheet

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number publisher, city and/or country where published.			
		Jacques van Helden et al., Representaing and Analysing Molecular and Cellular Function Using the Computer, Biol. Chem,XP008032491, September/October 2000, Vol. 381, pp. 921-935, Walter de Gruyter, Berlin & New York			
		Diane E. Oliver et al., Ontology Development For A Pharmacogenetics Knowledge Base, Stanford Medical Informatics, Stanford University of Medicine, January 23, 2002, pp. 65-76, XP002287419, Retrieved from Internet: <u>URL:http://lelix-web.stanford.edu/psb02/o1iver.pdf</u>			
		Peter D. Karp et al., Integrated pathway-genome databases and their role in drug discovery, Trends in Biotechnology, XP004169726, July 1999, pp. 275-281, Vol. 17, Elsevier Science			
		Andrey Rzhetsky, Ph.D. et al., A Knowledge Model for Analysis and Simulation of Regulatory networks in Bioformatics Studied Aiming at Disease Gene Discovery, AMIA 99 Fall Annual Symposium, PP1-5, XP002287421, Retrieved from the Internet: URL:http://www.amia.org/pubs/proceedings/symposia/1999/D005314.pdf			
		C.A. Goble et al., Transparent Access to Multiple Bioinformatics Information Sources, XP-001116348, IBM Systems Journal, 2001, pp. 532-551, Vol. 40, No. 2, IBM Corp. Armonk, New York			

Examiner	Date	
signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

2587611_1.DOC Attorney Docket No. 27763-705.831

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.